**Proteins** 

# LM-1484

**Molecular Weight:** 

Pathway:

Cat. No.: HY-101686 CAS No.: 197506-02-8

Molecular Formula:  $C_{28}H_{24}N_4O_3$ 

Target: Leukotriene Receptor

Please store the product under the recommended conditions in the Certificate of Storage:

Analysis.

GPCR/G Protein

464.52

**Product** Data Sheet

## **BIOLOGICAL ACTIVITY**

Description	LM-1484 is an antagonist of CysLT1 receptor and displays a higher affinity for <sup>3</sup> H-LTC4 sites.	
IC <sub>50</sub> & Target	CysLT <sub>1</sub>	LTC <sub>4</sub>
In Vitro	LM-1484 (10 $\mu$ M) induces the dissociation of $^3$ H-LTD4, and is able to displace $^3$ H-LTC4 from its binding sites $^{[1]}$ . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

### **PROTOCOL**

Kinase Assay [1]

Equilibrium binding studies are performed at 25°C for 60 min with 0.03-0.5 nM <sup>3</sup>H-LTD4 or 40 min with 0.03-0.5 nM <sup>3</sup>H-LTC4 and unlabeled homologous or heterologous ligands at the indicated concentrations. A multiligand protocol is followed. Ten micromolar S-decyl-GSH is present only in the case of <sup>3</sup>H-LTC4 equilibrium experiments. Time-courses are performed at 25°C with 0.5 nM <sup>3</sup>H-LTC4 or <sup>3</sup>H-LTD4. Dissociation is induced by adding 1 mM unlabeled leukotriene (homologous dissociation) or 10 µM unlabeled antagonist (heterologous dissociation). In both equilibrium and kinetic studies HLP membranes (0.25 mg per sample), 10 mM HEPES-KOH pH 7.4, 1 mM CaCl<sub>2</sub> and 1 mM MgCl<sub>2</sub> are added to the incubation mixture to achieve a final volume of 250 mL. All the experiments have been performed under control metabolic conditions. Unbound ligand is separated by rapid vacuum filtration onto glass-fiber GF/C filters soaked in 2.5% polyvinylalchool and the filters are washed twice with 4 mL of HEPES buffer at 4°C. Radioactivity is measured in a liquid scintillation counter. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### **REFERENCES**

[1]. Ravasi S, et al. Pharmacological differences among CysLT(1) receptor antagonists with respect to LTC(4) and LTD(4) in human lung parenchyma. Biochem Pharmacol. 2002 Apr 15;63(8):1537-46.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$ 

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 1 www.MedChemExpress.com